<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588965</url>
  </required_header>
  <id_info>
    <org_study_id>IRB07-00418</org_study_id>
    <secondary_id>NIH grant, GCRC MO1 RR000080</secondary_id>
    <nct_id>NCT00588965</nct_id>
  </id_info>
  <brief_title>Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects</brief_title>
  <official_title>Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background. In congenital long QT syndrome type 1 (LQT1), episodes of ventricular tachycardia
      are usually triggered by exercise and can be prevented in most patients by beta-blocker
      therapy. In addition, LQT1 associated with a normal resting QT interval can be unmasked by
      the abnormal QT response to exercise testing (failure of the QT interval to shorten
      normally). Preliminary data from our laboratory show that the exercise QT intervals of
      patients with LQT1 are partially normalized by beta-blocker therapy. It is still currently
      not known if beta-blockers modify the QT/heart rate relationship (a primary effect on
      repolarization) or if the &quot;normalizing&quot; effect is due to the inability of subjects on
      beta-blockers to attain sufficiently high workloads (due to reduced heart rate) for
      prolongation to occur. Moreover, the physiologic response of the exercise QT interval to
      beta-blockers in healthy control subjects is not known.

      Objective. The objective of this study is to define the impact of beta-blocker therapy on the
      QT response to exercise and recovery in normal subjects.

      Methods. Approximately 36 healthy adult subjects age-matched to previously studied LQT1
      subjects will undergo 1) screening history, 2) two weeks of beta-blocker therapy ending in an
      exercise test, and 3) two weeks of placebo therapy ending in an exercise test. Beta blocker
      and placebo will be given in random order in a double-blind fashion. The QT response to
      exercise and recovery will be compared between drug-free and beta-blocker-treated states.
      These data will be compared to those previously collected for LQT1 subjects.

      Implications. These results will provide new information about the effect of beta-blocker
      therapy on repolarization parameters in normal subjects, and will provide a context in which
      to interpret the previous findings that beta-blocker administration modifies the QT response
      to exercise in LQT1 subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTc Response to Exercise on Versus Off Beta-blocker.</measure>
    <time_frame>2 weeks on each treatment then exercise test</time_frame>
    <description>To minimize the effect of heart rate on QT, QT was measured at heart rates between 100 and 110 beats per minute during exercise (on and off beta-blocker) and during recovery (on and off beta-blocker).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tpeak-end Interval (Tpe)</measure>
    <time_frame>Measured after 2 weeks on each intervention</time_frame>
    <description>Tpeak-end interval was measured at rest, exercise, and recovery on placebo and on propranolol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Long QT Syndrome</condition>
  <condition>Cardiac Repolarization</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are assigned to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol LA</intervention_name>
    <description>Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy normal adults, age- and gender-matched to previously studied LQT1 subjects

        Exclusion Criteria:

          -  Cardiac disease

          -  Diabetes

          -  Hypertension

          -  Severe allergic reaction

          -  Asthma requiring treatment

          -  Use of medications other than oral contraceptives, acetaminophen, nonsteroidal
             anti-inflammatory drugs, or synthroid or other thyroid medications

          -  Pregnancy (subjects will be asked if they are pregnant)

          -  Inability to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth S Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>July 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2013</results_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Elizabeth S. Kaufman, MD</investigator_full_name>
    <investigator_title>Professor, Case Western Reserve University</investigator_title>
  </responsible_party>
  <keyword>QT interval</keyword>
  <keyword>beta-blocker</keyword>
  <keyword>exercise</keyword>
  <keyword>electrocardiogram</keyword>
  <keyword>repolarizaton</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants were randomized to one of 2 sequences, in which they received either propranolol first, then placebo, or placebo first, then propranolol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Subjects will take propranolol LA 80 mg or placebo daily for one week then propranolol LA 160 mg for one week or 2 placebo pills, followed by the exercise test. The participants will be randomized to one of 2 sequences: placebo first or propranolol first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>QTc Response to Exercise on Versus Off Beta-blocker.</title>
        <description>To minimize the effect of heart rate on QT, QT was measured at heart rates between 100 and 110 beats per minute during exercise (on and off beta-blocker) and during recovery (on and off beta-blocker).</description>
        <time_frame>2 weeks on each treatment then exercise test</time_frame>
        <population>Please note that this was a crossover study. There were 35 subjects and each subject completed both the placebo and beta-blocker arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
          </group>
        </group_list>
        <measure>
          <title>QTc Response to Exercise on Versus Off Beta-blocker.</title>
          <description>To minimize the effect of heart rate on QT, QT was measured at heart rates between 100 and 110 beats per minute during exercise (on and off beta-blocker) and during recovery (on and off beta-blocker).</description>
          <population>Please note that this was a crossover study. There were 35 subjects and each subject completed both the placebo and beta-blocker arm.</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" spread="17"/>
                    <measurement group_id="O2" value="317" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317" spread="13"/>
                    <measurement group_id="O2" value="315" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tpeak-end Interval (Tpe)</title>
        <description>Tpeak-end interval was measured at rest, exercise, and recovery on placebo and on propranolol.</description>
        <time_frame>Measured after 2 weeks on each intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Propranolol</title>
          </group>
        </group_list>
        <measure>
          <title>Tpeak-end Interval (Tpe)</title>
          <description>Tpeak-end interval was measured at rest, exercise, and recovery on placebo and on propranolol.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="13"/>
                    <measurement group_id="O2" value="72" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="13"/>
                    <measurement group_id="O2" value="61" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="19"/>
                    <measurement group_id="O2" value="68" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects are assigned to placebo.</description>
        </group>
        <group group_id="E2">
          <title>Propranolol</title>
          <description>Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Kaufman</name_or_title>
      <organization>MetroHealth Medical Center</organization>
      <phone>216-778-2349</phone>
      <email>ekaufman@metrohealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

